DRAXXIN tulathromycin, is the first entry of a novel macrolide subclass, the triamilides, developed by Pfizer Animal Health. DRAXXIN is now the first-line product-of-choice to treat BRD, offering both superior disease treatment as well as outstanding efficacy for the control of BRD in cattle at high risk of developing the disease.
|
Features:
- Superior efficacy to treat bovine respiratory disease (BRD).1,2,3
- Convenient, full course of therapy in a single dose.
- Effectiveness against the three major BRD pathogens.
- Mannheimia (Pasteurella) haemolytica
- Pasteurella multocida
- Histophilus somni (Haemophilus somnus)
- Excellent first BRD treatment response.1,2,3
- Remarkably lower mortalities and chronics due to BRD.1,2,3
- Effective control of BRD in cattle at high risk of developing
|
|
draxxin 
